Cargando…

Impact on in-hospital mortality of ceftaroline versus standard of care in community-acquired pneumonia: a propensity-matched analysis

The purpose of this study is to evaluate the in-hospital mortality of community-acquired pneumonia (CAP) treated with ceftaroline in comparison with standard therapy. This was a retrospective observational study in two centers. Hospitalized patients with CAP were grouped according to the empiric reg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cilloniz, Catia, Mendez, Raúl, Peroni, Héctor, Garcia-Vidal, Carolina, Rico, Verónica, Gabarrus, Albert, Menéndez, Rosario, Torres, Antoni, Soriano, Alex
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8588767/ https://www.ncbi.nlm.nih.gov/pubmed/34767120 http://dx.doi.org/10.1007/s10096-021-04378-0

Ejemplares similares

Ceftaroline in severe community-acquired pneumonia
por: Cilloniz, Catia, et al.
Publicado: (2022)

Outcomes of Critically Ill Very Old Patients With Community-Acquired Pneumonia and Acute Respiratory Distress Syndrome
por: Cillóniz, Catia, et al.
Publicado: (2022)

Lymphopenia Is Associated With Poor Outcomes of Patients With Community-Acquired Pneumonia and Sepsis
por: Cilloniz, Catia, et al.
Publicado: (2021)

Lymphopenic Community Acquired Pneumonia (L-CAP), an Immunological Phenotype Associated with Higher Risk of Mortality
por: Bermejo-Martin, Jesus F., et al.
Publicado: (2017)

Effect of Corticosteroids on C-Reactive Protein in Patients with Severe Community-Acquired Pneumonia and High Inflammatory Response: The Effect of Lymphopenia
por: Torres, Antoni, et al.
Publicado: (2019)

Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistant Staphylococcus aureus pneumonia
por: Torres, Antoní, et al.
Publicado: (2023)

Defining Community-Acquired Pneumonia as a Public Health Threat: Arguments in Favor from Spanish Investigators
por: Cillóniz, Catia, et al.
Publicado: (2020)

Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial
por: Ceccato, Adrian, et al.
Publicado: (2017)

Bacterial co-infection with H1N1 infection in patients admitted with community acquired pneumonia
por: Cillóniz, Catia, et al.
Publicado: (2012)

The Value of C-Reactive Protein-to-Lymphocyte Ratio in Predicting the Severity of SARS-CoV-2 Pneumonia
por: Cillóniz, Catia, et al.
Publicado: (2021)

Twenty-year trend in mortality among hospitalized patients with pneumococcal community-acquired pneumonia
por: Cillóniz, Catia, et al.
Publicado: (2018)

Community-acquired polymicrobial pneumonia in the intensive care unit: aetiology and prognosis
por: Cillóniz, Catia, et al.
Publicado: (2011)

Ceftaroline
por: Soriano, Alex
Publicado: (2021)

Severe community-acquired pneumonia: Characteristics and prognostic factors in ventilated and non-ventilated patients
por: Ferrer, Miquel, et al.
Publicado: (2018)

Host-targeted approaches to sepsis due to community-acquired pneumonia
por: Cilloniz, Catia, et al.
Publicado: (2022)

Risk and Prognostic Factors in Very Old Patients with Sepsis Secondary to Community-Acquired Pneumonia
por: Cillóniz, Catia, et al.
Publicado: (2019)

Impact of Cefotaxime Non-susceptibility on the Clinical Outcomes of Bacteremic Pneumococcal Pneumonia
por: Cillóniz, Catia, et al.
Publicado: (2019)

Multidrug Resistant Gram-Negative Bacteria in Community-Acquired Pneumonia
por: Cillóniz, Catia, et al.
Publicado: (2019)

Predicting treatment failure in patients with community acquired pneumonia: a case-control study
por: Martin-Loeches, Ignacio, et al.
Publicado: (2014)

PES Pathogens in Severe Community-Acquired Pneumonia
por: Cillóniz, Catia, et al.
Publicado: (2019)

Characteristics and Management of Community-Acquired Pneumonia in the Era of Global Aging
por: Cillóniz, Catia, et al.
Publicado: (2018)

Pneumococcal Serotypes Associated with Community-Acquired Pneumonia Hospitalizations in Adults in Spain, 2016–2020: The CAPA Study
por: Menéndez, Rosario, et al.
Publicado: (2023)

Real-world corticosteroid use in severe pneumonia: a propensity-score-matched study
por: Ceccato, A., et al.
Publicado: (2021)

Cytokine Activation Patterns and Biomarkers Are Influenced by Microorganisms in Community-Acquired Pneumonia
por: Menéndez, Rosario, et al.
Publicado: (2012)

Lymphocytopenia as a Predictor of Mortality in Patients with ICU-Acquired Pneumonia
por: Ceccato, Adrian, et al.
Publicado: (2019)

Remdesivir and survival outcomes in critically ill patients with COVID-19: A multicentre observational cohort study
por: Cillóniz, Catia, et al.
Publicado: (2023)

Time to blood culture positivity as a predictor of clinical outcomes and severity in adults with bacteremic pneumococcal pneumonia
por: Cillóniz, Catia, et al.
Publicado: (2017)

The Evolution and Distribution of Pneumococcal Serotypes in Adults Hospitalized With Community-Acquired Pneumonia in Spain Using a Serotype-Specific Urinary Antigen Detection Test: The CAPA Study, 2011–2018
por: Torres, Antoni, et al.
Publicado: (2021)

Early Initiation of Corticosteroids Might be Harmful in Patients Hospitalized With COVID-19 Pneumonia: A Multicenter Propensity Score Analysis
por: Pérez de Llano, Luis A., et al.
Publicado: (2022)

Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia
por: Maselli, Diego J, et al.
Publicado: (2012)

Ceftaroline Fosamil for the Treatment of Community-Acquired Pneumonia: from FOCUS to CAPTURE
por: Carreno, Joseph J., et al.
Publicado: (2014)

Biomarkers in Community-Acquired Pneumonia (Cardiac and Non-Cardiac)
por: Méndez, Raúl, et al.
Publicado: (2020)

Addendum: Cillóniz, C.; Dominedò, C.; Nicolini, A.; Torres, A. PES Pathogens in Severe Community-Acquired Pneumonia. Microorganisms 2019, 7, 49
por: Cillóniz, Catia, et al.
Publicado: (2019)

Critical appraisal of ceftaroline in the management of community-acquired bacterial pneumonia and skin infections
por: Goodman, Julian J, et al.
Publicado: (2012)

Ceftaroline in the management of complicated skin and soft tissue infections and community acquired pneumonia
por: Mpenge, Mbiye A, et al.
Publicado: (2015)

Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia in the intensive care unit
por: Maggiore, Christy, et al.
Publicado: (2015)

809 Contemporary Experience with Ceftaroline Fosamil for the Treatment of Community-acquired Bacterial Pneumonia
por: Johnson, Leonard B, et al.
Publicado: (2014)

Community-acquired pneumonia in critically ill very old patients: a growing problem
por: Cillóniz, Catia, et al.
Publicado: (2020)

Ceftobiprole for the treatment of pneumonia
por: Cillóniz, Catia, et al.
Publicado: (2019)

Lymphopenic community acquired pneumonia as signature of severe COVID-19 infection
por: Bermejo-Martin, Jesús F, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3ahu6e650m3kpmq5a7ljo701ua